Answers are grounded in this paper and cite their sources.
Mitomycin-C (MMC) is the most widely used agent for hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal peritoneal metastases, though dosing and intervals vary across institutions. This study aimed to compare the pharmacokinetic profiles of three MMC-based HIPEC regimens. Eighteen male Sprague–Dawley rats were randomized into three groups for 90 min of HIPEC at 41–42℃. Group 1 received 35 mg/m² in three divided doses at 0, 30, and 60 min; Group 2 received 40 mg/m² in two divided doses at 0 and 60 min; Group 3 received a single bolus dose of 35 mg/m² at HIPEC initiation. Peritoneal fluid and plasma concentrations were measured by liquid chromatography-tandem mass spectrometry. MMC concentrations differed significantly across groups over the 90-minute perfusion period ( p < 0.001). Peritoneal concentrations at 90 min were comparable among groups (73.63 vs. 75.92 and 79.58 ng/mL), whereas the plasma concentration was lower in Group 1 (1.59 vs. 2.45 and 2.02 ng/mL; p = 0.043). The peritoneal-to-plasma AUC ratios were comparable among groups (52.1 vs. 47.7 vs. 47.1, respectively; p = 0.849). In conclusion, the three MMC-based HIPEC protocols showed no significant differences in the peritoneal-to-plasma AUC ratio, although Group 1 demonstrated lower plasma MMC concentrations.
No takes yet. Share an insight, caveat, or question.
Joo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: